Skip to content
Triangle logo TriangleGet started
← Study library

NCT02289222 · REGISTRY CONDITION SEARCH

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
TERMINATED
Registry last update
2019-11-05

This is an open label trial of Anti PD1/MD-3475, Pomalidomide and dexamethasone. The study will use standard (FDA approved) doses for both pomalidomide and dexamethasone. The experimental drug Anti PD-1 (MK 3475) given on days 1 and 14.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

The Number of Participants With Adverse Events

→

outcome · POSTED

PD-LI Expression On Myeloma Cells

→

outcome · POSTED

Time to Progression Free Survival (PFS)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: 1. Confirmed diagnosis of relapsed and/or refractory MM according to International Myeloma Working Group guidelines (2003) 2. Received two lines of prior therapy that includes an IMiD (lenalidomide or thalidomide) and a proteasome inhibitor (bortezomib and/or carfilzomib) (used either separately or in combination). (a). Prior pomalidomide therapy is permitted, provided the patient achieved at least a partial remission and had not progressed for 3 months after stopping therapy. 3. Measureable disease as defined by the protocol (assessed within 28 days prior to registration). 4. Be willing and able to provide written informed consent/assent for the trial. 5. Be over 18 years of age on day of signing informed consent. 6. Have a performance status of 2 on the ECOG Performance Scale. 7. Demonstrate adequate organ function as defined by the protocol. 8. Female subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study drug. 9. Male subjects should agree to use an adequate method of contraception. Exclusion Criteria: 1. Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment. 2. Has a diagnosis of immunodeficiency (HIV) or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. 3. Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. 4. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. (Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.) 5. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or situ cervical cancer that has undergone potentially curative therapy. 6. Has known active central nervous system disease and/or carcinomatous meningitis. 7. Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. 8. Has evidence of interstitial lung disease or active, non-infectious pneumonitis. 9. Has an active infection requiring systemic therapy. 10. Has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. 11. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 12. Pregnant or breastfeeding, or expecting to conceive or father children during study participation. 13. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody as per the protocol. 14. has known active Hepatitis B or Hepatitis C. 15. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies) 16. Has received a live vaccine within 30 days prior to the first dose of trial treatment.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Pomalidomide is given at standard dose of 4 mg daily orally for 21 days and dexamethasone is given at 40 mg orally weekly. MK3475 will be given as an intravenous infusion at 200 mg every 2 weeks (days 1 and 14).
    intervention Names
    1. Drug: MK-3475
    2. Drug: Pomalidomide
    3. Drug: Dexamethasone
    label
    Pomalidomide, Dexamethasone & MK-3475
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Pomalidomide, Dexamethasone & MK-3475
    description
    Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
    name
    MK-3475
    other Names
    1. Generic name: Pembrolizumab - Trade name: Keytruda
    type
    DRUG
  2. arm Group Labels
    1. Pomalidomide, Dexamethasone & MK-3475
    description
    Pomalidomide is given at standard dose of 4 mg daily orally for 21 days
    name
    Pomalidomide
    other Names
    1. Pomalyst, CC-4047, Actimid
    type
    DRUG
  3. arm Group Labels
    1. Pomalidomide, Dexamethasone & MK-3475
    description
    Dexamethasone is given at 40 mg orally weekly
    name
    Dexamethasone
    other Names
    1. Decadron
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
48
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Establish the safety and tolerability of Pomalidomide and Dexamethasone in combination with MK-3475
    measure
    The Number of Participants With Adverse Events
    time Frame
    24 month
secondary Outcomes
  1. description
    The identification of a biomarker for response by evaluating PD-1/PDL-1 expression in patients' bone marrow aspirate samples will be analyzed in order to help select patients for future anti-PD-1 therapy. The main exploratory biomarker analysis was to examine potential correlation between expression of PD-1 on T cells and PD-L1 on myeloma cells with clinical outcome using the following parameters: response rate focusing on responses ≥ very good partial response (VGPR) and PFS. SAS software (v.9.4; SAS Institute, Inc, Cary, NC) was used for statistical analyses.
    measure
    PD-LI Expression On Myeloma Cells
    time Frame
    Tissue sample collection will take place before starting study therapy with MK-3475 at baseline and again at time of relapse as defined by the International Myeloma Working Group Response Criteria (Average of up to 24months)
  2. description
    PFS will be measured in all participants. Survival and PFS functions were estimated using the Kaplan-Meier method. The Cox regression model was used to assess the following plausible risk factors for OS and PFS: age, isotype, number of cycles of therapy, and cytogenetic profile.
    measure
    Time to Progression Free Survival (PFS)
    time Frame
    PFS assessments will take place after starting study therapy with MD-3475 and will continue until the start of a new anti-neoplastic therapy, disease progression, death, or the end of study up to an average of 24 months.
Full study description
brief Summary
This is an open label trial of Anti PD1/MD-3475, Pomalidomide and dexamethasone. The study will use standard (FDA approved) doses for both pomalidomide and dexamethasone. The experimental drug Anti PD-1 (MK 3475) given on days 1 and 14.
detailed Description
This phase I/II study is focused on patients with relapsed or refractory multiple myeloma. MK-3475 will be given as an intravenous infusion at every 2 weeks. Treatment will be administered on an outpatient basis.
Source references
references
  1. citation
    Badros A, Hyjek E, Ma N, Lesokhin A, Dogan A, Rapoport AP, Kocoglu M, Lederer E, Philip S, Milliron T, Dell C, Goloubeva O, Singh Z. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017 Sep 7;130(10):1189-1197. doi: 10.1182/blood-2017-03-775122. Epub 2017 May 1.
    pmid
    28461396
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-e6b4c50bf85bca278979
      requested nct id
      NCT02289222
      primary nct id
      NCT02289222
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      f61b5b8281f834a98709317598003056a2aa82c9b92a292e3623f400c9c3291b
      payload sha256
      bf4d5c7156ec7ccf060e99d49367d28bf507ca836f0214170c494115c07eb7ba
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-e6b4c50bf85bca278979
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02289222
      occurrences
      1. context exact
        NCT02289222
        end
        11
        exact text
        NCT02289222
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-001.json
      source file sha256
      f61b5b8281f834a98709317598003056a2aa82c9b92a292e3623f400c9c3291b
      source json pointer
      /studies/29/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      f49e25774bcd8956c621c21e82f7907bb28c7a7ca7a2d14f0001ab22e265678b

    Preserved source evidence · Not medical advice